NEW YORK (GenomeWeb) – MDxHealth has exclusively licensed Ghent University's proprietary molecular diagnostic visualization technology to enable the detection of cancer associated epigenetic changes in both tissue and liquid samples, the company said today.

Separately, the two parties forged a research and development agreement to develop in vitro diagnostic kits and laboratory-developed tests based on the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.